Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 8

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 8
---
 US shareholders now represent our largest investor group. The US has the world’s largest and most liquid public markets by capitalisation, and the largest pool of innovative biopharma companies and investors. AstraZeneca’s scientific and commercial achievements have been underpinned by its continuous adaptation to a rapidly changing and dynamic industry environment. The same approach needs to be followed in terms of access to capital markets. The Board is determined to ensure that the Group has the flexibility to access the broadest available pool of capital including in the US. It is expected that the Harmonised Listing Structure will widen the pool of investors in AstraZeneca, especially US domestic institutional and retail investors. If approved by Shareholders, the proposed Harmonised Listing Structure would be for the benefit of the Company as a whole as it will result in the AstraZeneca Shares becoming directly listed on the NYSE alongside the existing listings of AstraZeneca Shares on the London Stock Exchange and Nasdaq Stockholm.

7

TABLE OF CONTENTS

Importantly, implementation of the proposed Harmonised Listing Structure will not change AstraZeneca’s current status as a UK incorporated, headquartered and tax resident company which will continue to be included in the FTSE 100 index and the OMX Stockholm 30 index.

AstraZeneca will remain bound by applicable UK governance principles and standards (including the Companies Act 2006 and the UK Corporate Governance Code) following the implementation of the Harmonised Listing Structure, and will continue to be subject to the City Code on Takeovers and Mergers.

The Harmonised Listing Structure proposal also reflects the weight the Board attaches to AstraZeneca’s long and distinguished heritage in the UK and Sweden. AstraZeneca is a truly global company, operating six global R&D centres on three continents, and active operationally and commercially in more than 125 countries. The proposed Harmonised Listing Structure will reinforce our global identity as we keep expanding and investing in our key markets.

Implementation of the Harmonised Listing Structure requires the termination of the existing ADR Programme and migration of the settlement system applicable to the AstraZeneca Shares, without any change in practice to Shareholders’ ownership rights in respect of such AstraZeneca Shares or the economic rights attaching to them (save in respect of fractional entitlements in respect of AstraZeneca ADSs).

This letter should be read in conjunction with the more detailed explanation set out in Part II ( Explanation of the proposals to implement the Harmonised Listing Structure ) of this document and the remainder of this document as